# Takuji Okusaka

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/takuji-okusaka/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,750 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 100 |
| i10-index | 400 |
| Last Known Institution | National Cancer Centre Japan |
| OpenAlex ID | https://openalex.org/A5076696174 |
| ORCID iD | https://orcid.org/0000-0003-1729-807X |
| Works | 948 |

## Researcher papers

- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators](https://scholariq.org/papers/whole-genome-sequencing-of-liver-cancers-identifies-etiological-influences-on/)
- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer](https://scholariq.org/papers/whole-genome-mutational-landscape-and-characterization-of-noncoding-and/)
- [Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study](https://scholariq.org/papers/randomized-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-or-gemcitabine/)
- [Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial](https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/)
- [Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study](https://scholariq.org/papers/nivolumab-alone-or-in-combination-with-cisplatin-plus-gemcitabine-in-japanese/)
- [Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-s-1-compared-with-observation-in-resected-biliary-tract-cancer-jcog1202/)
- [Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis](https://scholariq.org/papers/clinical-practice-guidelines-for-pancreatic-cancer-2022-from-the-japan-pancreas/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)

## Researcher university

- [National Cancer Centre Japan](https://scholariq.org/institutions/national-cancer-centre-japan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.